Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders

Haematologica

Volumn 101, Issue 1, 2016, Pages 38-45

  de Swart, Louise ^a   Hendriks, Jan C M ^a   van der Vorm, Lisa N ^a   Cabantchik, Z Ioav ^b   Evans, Patricia J ^c   Hod, Eldad A ^d   Brittenham, Gary M ^d   Furman, Yael ^e   Wojczyk, Boguslaw ^d   Janssen, Mirian C H ^a   Porter, John B ^c   Mattijssen, Vera E J M ^f   Biemond, Bart J ^g   Mackenzie, Marius A ^a   Origa, Raffaella ^h   Galanello, Renzo ^h   Hider, Robert C ⁱ   Swinkels, Dorine W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e Aferrix Ltd   (Israel)

^f RIJNSTATE HOSPITAL   (Netherlands)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF CAGLIARI   (Italy)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; IRON; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; TRANSFERRIN;

ADULT; AGED; ARTICLE; BETA THALASSEMIA; COLORIMETRY; FEMALE; HEMOCHROMATOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; NEWBORN; PHLEBOTOMY; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; YOUNG ADULT; BETA-THALASSEMIA; BLOOD; BLOOD TRANSFUSION; METABOLISM; MYELODYSPLASTIC SYNDROMES;

ADULT; AGED; BETA-THALASSEMIA; BLOOD TRANSFUSION; FEMALE; HEMOCHROMATOSIS; HUMANS; IRON; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSFERRIN;

EID: 84952945274     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.133983     Document Type: Article

References (40)

1. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40(2):255-263.
2. Le Lan C, Loreal O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood. 2005;105(11): 4527-4531.
3. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in ironoverloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood. 2004;104(5):1504-1510.
4. Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrinbound iron. Blood. 2011;118(25): 6675-6682.
5. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012;1820(3):403-410.
6. Hider RC, Silva AM, Podinovskaia M, Ma Y. Monitoring the efficiency of iron chelation therapy: the potential of nontransferrinbound iron. Ann NY Acad Sci. 2010; 1202:94-99.
7. Silva AM, Hider RC. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim Biophys Acta. 2009;1794(10):1449-1458.
8. Silva AM, Kong X, Parkin MC, Cammack R, Hider RC. Iron(III) citrate speciation in aqueous solution. Dalton Trans. 2009;(40):8616-8625.
9. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrinbound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989;264(8):4417-4422.
10. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97(3):792-798.
11. Breuer W, Ghoti H, Shattat A, et al. Nontransferrin bound iron in thalassemia: differential detection of redox active forms in children and older patients. Am J Hematol. 2012;87(1):55-61.
12. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7):2670-2677.
13. Cabantchik ZI. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front Pharmacol. 2014;5(45):1-11.
14. Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13(1):57-74.
15. Ma Y, Podinovskaia M, Evans PJ, et al. A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry. Biochem J. 2014;463(3):351-362.
16. Pierre JL, Gautier-Luneau I. Iron and citric acid: a fuzzy chemistry of ubiquitous biological relevance. Biometals. 2000;13(1):91-96.
17. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010; 1800(8):760-769.
18. Wood JC. Guidelines for quantifying iron overload. Hematology Am Soc Hematol Educ Program. 2014;2014 (1):210-215.
19. Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29-33.
20. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
21. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143-1150.
22. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. Br J Haematol. 2009;147(5):744-751.
23. Wood JC, Glynos T, Thompson A, et al. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011;96(7):1055-1058.
24. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann NY Acad Sci. 2010;1202:1-9.
25. Evans PJ, Halliwell B. Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays. Methods Enzymol. 1994;233:82-92.
26. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem. 1990;186 (2):320-323.
27. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of nontransferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273(2):212-220.
28. Zhang D, Okada S, Kawabata T, Yasuda T. An improved simple colorimetric method for quantitation of non-transferrin-bound iron in serum. Biochem Mol Biol Int. 1995;35(3):635-641.
29. Aferrix. www.aferrix.com. July 2015.
30. Jacobs EM, Hendriks JC, van Tits BL, et al. Results of an international round robin for the quantification of serum non-transferrinbound iron: need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005;341(2):241-250.
31. Makino T, Nakamura K, Takahara K. Potential problems in the determination of serum non-transferrin-bound iron using nitrilotriacetic acid and ultrafiltration. Clin Chim Acta. 2014;429:12-13.
32. Sasaki K, Ikuta K, Tanaka H, et al. Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination. Mol Med Rep. 2011;4(5): 913-918.
33. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest. 2002;32 (Suppl 1): 50-54.
34. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood. 2000;95(9):2975-2982.
35. Itkonen O, Vaahtera L, Parkkinen J. Comparison of bleomycin-detectable iron and labile plasma iron assays. Clin Chem. 2013;59(8):1271-1273.
36. Danjou F, Cabantchik ZI, Origa R, et al. A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica. 2014;99(3):e38-40.
37. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80 (2):168-176.
38. Domenica Cappellini M, Tavazzi D, Duca L, Marelli S, Fiorelli G. Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia. Transfus Sci. 2000;23(3):245-246.
39. Inati A, Musallam KM, Cappellini MD, Duca L, Taher AT. Nontransferrin-bound iron in transfused patients with sickle cell disease. Int J Lab Hematol. 2011;33(2):133-137.
40. Taher A, Musallam KM, El Rassi F, et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5):569-572.